Report of the 6th International Workshop on PET in lymphoma

Abstract

Two hundred and ten nuclear medicine physicians, radiologists, and hematologists from 26 countries attended the 6th International Workshop on Positron Emission Tomography (PET) in Lymphoma and Myeloma held in Menton, France, in September 2016. The meeting was under the auspices of the European Lymphoma Institute (ELI), the European Association of Nuclear Medicine (EANM) the Lymphoma Study Association (LYSA), the Italian Foundation on Lymphoma (FIL) and the Carnot Institute for Lymphoma (CALYM). Forty scientific posters were presented. For the first time, specialists in the field of multiple myeloma (MM) were involved in the expert session. The aim was to establish from the experience of Italian and French studies new guidelines of FDG-PET/CT reporting for myeloma staging and restaging. The meeting dedicated an entire session to MM imaging followed by a session on the role of PET in Peripheral T cell Lymphoma. An entire session addressed the issues of Deauville scale particularly for end treatment assessment and the challenging consequences of immunomodulatory treatments on PET reporting. A specific session presented the potential role of baseline metabolic tumor measurement to predict outcome and identify different risk categories and the main results obtained in different lymphoma entities were described. Whether it could replace clinical staging has been extensively discussed. The more recent results obtained in the H10 trial have been presented and compared to the published data in early stage Hodgkin lymphoma. Finally, the ongoing studies using PET for guiding therapeutic strategies have been reported by the various lymphoma cooperative groups that participated to the meeting.

FDG PET/CT as a diagnostic and prognostic tool for the evaluation of marginal zone lymphoma

“…Response to treatment, meaning I‐PET/CT and E‐PET/CT, were reported by VAS, SUVmax, and the Deauville 5‐point score (DS) evaluation for response assessment . A DS of greater than or equal to 3 was considered positive.…”

“…17 Response to treatment, meaning I-PET/CT and E-PET/CT, were reported by VAS, SUVmax, 16 and the Deauville 5-point score (DS) evaluation for response assessment. 18 A DS of greater than or equal to 3 was considered positive. The PET/CT findings were considered positive if they were positive using any one of these three evaluation methods.…”

Quantitative assessment of interim PET in Hodgkin lymphoma: An evaluation of the qPET method in adult patients in the RAPID trial

“…Recent studies have explored responseadapted treatment [5][6][7] including omission of radiotherapy in patients with a complete metabolic response (CMR) to chemotherapy [8][9][10][11]. Interim F-18-FDG-PET (iPET) has proved to be a reliable imaging tool for early treatment adaptation [12][13][14][15][16]. The current standard for iPET evaluation is the Lugano classification, which uses the Deauville score (DS), a five-point ordinal scale, to grade residual uptake, if present, in sites initially involved by lymphoma [17].…”

Interim FDG-PET in lymphoma, a questionable practice in hematology

“…The 2014 Lugano criteria [5,6] and 2016 refinement of the Lugano criteria [7] not only promote performing FDG-PET scans after treatment, but also during treatment, also known as interim FDG-PET. These examinations are also promoted by other guidelines such as the guidelines of the European Society of Oncology (ESMO) [8,9] and the National Comprehensive Cancer Network (NCCN) [10,11], and the value of these examinations are hyped at conference meetings [12][13][14]. Consequently, interim FDG-PET scanning is adopted worldwide at numerous institutions, and thousands of lymphoma patients undergo an interim FDG-PET evaluation every year.…”